Bushen Huoxue Formula （补肾活血方） Combined with Conventional Western Medicine for 129 Patients of Heart Failure with Mid-range Ejection Fraction with Syndrome of Qi Deficiency and Blood Stasis：A Randomized Controlled Trial
10.13288/j.11-2166/r.2024.04.008
- VernacularTitle:补肾活血方联合常规西药治疗射血分数中间值心衰气虚血瘀证患者129例随机对照临床观察
- Author:
Yan ZHANG
1
;
Jia HE
2
;
Wei ZHANG
3
;
Tingting SONG
4
Author Information
1. The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine， Shenyang， 110032
2. The Fourth Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
3. Liaoning University of Traditional Chinese Medicine
4. The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
- Publication Type:Journal Article
- Keywords:
chronic heart failure;
qi deficiency and blood stasis;
Bushen Huoxue Formula （补肾活血方）;
heart-kidney related
- From:
Journal of Traditional Chinese Medicine
2024;65(4):376-381
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the clinical effectiveness of Bushen Huoxue Formula （补肾活血方） in the treatment of heart failure with mid-range ejection fraction. MethodsA total of 277 patients of heart failure with mid-range ejection fraction with syndrome of qi deficiency and blood stasis were randomly divided into the treatment group （139 cases） and the control group （138 cases）. The control group was given conventional western medicine， and the treatment group was given Bushen Huoxue Formula on the basis of the control group. Both groups were treated for 8 weeks. Left ventricular ejection fraction （LVEF）， N-terminal B-type natriuretic peptide （NT-pro BNP） level， cardiac function grade， Minnesota heart failure quality of life score， anxiety score， depression score， and the major incidence of cardiovascular adverse events and re-hospitalization rate after 6-month treatment were compared between the two groups before and after treatment. ResultsThere were 10 withdrawals in the treatment group and 6 withdrawals in the control group， so 129 cases in the treatment group and 132 cases in the control group completed the trial. After treatment， LVEF increased and NT-pro BNP level decreased in both groups （P＜0.05）； compared with those in the control group， LVEF increased and NT-pro BNP level decreased in the treatment group （P＜0.05）. The total rate of graded improvement of cardiac function in the treatment group （97.67%， 126/129 cases） was higher than that in the control group （84.09%， 111/132 cases） （P＜0.05）. After treatment， the Minnesota heart failure quality of life score， anxiety score， and depression score were lower in both groups （P＜0.05）， and the above scores in the treatment group were lower than those in the control group （P＜0.05）. After 6-month treatment， there was no death event in both groups， and there was no significant difference in the major incidence of cardiovascular adverse events between the treatment group （25.58%， 33/129 cases） and the control group （33.33%， 44/132 cases） （P＞0.05）. The rate of re-hospitalization in treatment group （14.73%， 19/129 cases） was lower than that in control group （30.30%， 40/132 cases） （P＜0.05）. ConclusionBushen Huoxue Formula can increase LVEF， reduce NT-pro BNP， improve quality of life， improve anxiety and depression， and reduce the rate of re-hospitalization in patients of heart failure with mid-range ejection fraction with syndrome of qi deficiency and blood stasis.
